Application of Multicriteria Decision Analysis to Determine the Value of Prophylaxis Relative to On-Demand Treatment in Hemophilia A and Emicizumab versus Replacement Therapy in the Greek Healthcare Setting

被引：0
|
作者：
George Gourzoulidis
Garyfallia Stefanou
Marina Economou
Sofia Vakalopoulou
George Filippidis
George Soultatis
Dimitrios Kontos
Sotiria Tzima
Fotis Ntemousis
Angeliki Fassa
Georgia Kourlaba
机构：
[1] University of West Attica,Department of Public Health Policy, School of Public Health
[2] ECONCARE LP,1st Pediatric Department
[3] Aristotle University Thessaloniki,2nd Propedeutic Department of Internal Medicine
[4] Hippocratio Hospital,undefined
[5] Hippokration General Hospital of Thessaloniki,undefined
[6] Aristotle University of Thessaloniki,undefined
[7] Greek Haemophilia Society,undefined
[8] Laiko General Hospital,undefined
[9] Panhellenic Pharmaceutical Association,undefined
[10] Roche Hellas S.A,undefined
来源：
Clinical Drug Investigation | 2022年 / 42卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：75 / 85
页数：10
相关论文
共 19 条
  • [1] Application of Multicriteria Decision Analysis to Determine the Value of Prophylaxis Relative to On-Demand Treatment in Hemophilia A and Emicizumab versus Replacement Therapy in the Greek Healthcare Setting
    Gourzoulidis, George
    Stefanou, Garyfallia
    Economou, Marina
    Vakalopoulou, Sofia
    Filippidis, George
    Soultatis, George
    Kontos, Dimitrios
    Tzima, Sotiria
    Ntemousis, Fotis
    Fassa, Angeliki
    Kourlaba, Georgia
    CLINICAL DRUG INVESTIGATION, 2022, 42 (01) : 75 - 85
  • [2] APPLICATION OF MULTI-CRITERIA DECISION ANALYSIS TO DETERMINE THE VALUE OF PROPHYLAXIS RELATIVE TO ON-DEMAND TREATMENT IN HAEMOPHILIA A AND EMICIZUMAB VERSUS REPLACEMENT THERAPY IN THE GREEK HEALTHCARE SETTING
    Gourzoulidis, G.
    Stefanou, G.
    Economou, M.
    Vakalopoulou, S.
    Filippidis, G.
    Soultatis, G.
    Kontos, D.
    Tzima, S.
    Ntemousis, F.
    Fassa, A.
    Kourlaba, G.
    HAEMOPHILIA, 2021, 27 : 45 - 45
  • [3] Application of a Value Framework to Determine the Value of Prophylaxis Versus On-Demand Treatment in Adults with Hemophilia A in China
    Baoying Tan
    Ailing Lin
    Rong Han
    Lu Bai
    Jing Sun
    Shanlian Hu
    Jianwei Xuan
    Advances in Therapy, 2025, 42 (4) : 1881 - 1891
  • [4] Value of prophylaxis vs on-demand treatment: Application of a value framework in hemophilia
    Nugent, Diane
    O'Mahony, Brian
    Dolan, Gerry
    HAEMOPHILIA, 2018, 24 (05) : 755 - 765
  • [5] COST-EFFECTIVENESS OF EMICIZUMAB PROPHYLAXIS THERAPY VERSUS RECOMBINANT ACTIVATED FVII ON-DEMAND THERAPY FOR HEMOPHILIA A WITH INHIBITORS IN CHINA
    Lin, Z.
    Ran, X.
    Liu, C.
    Xuan, J.
    VALUE IN HEALTH, 2022, 25 (01) : S119 - S120
  • [6] COST ANALYSIS OF BYPASSING AGENT PROPHYLAXIS TREATMENT VERSUS ON-DEMAND THERAPY IN HEMOPHILIA A WITH INHIBITOR IN SPAIN
    Villarrubia, R.
    Oyagueez, I
    Alvarez, M. T.
    Mingot, E.
    Parra, R.
    Casado, M. A.
    VALUE IN HEALTH, 2013, 16 (07) : A380 - A380
  • [7] COST-EFFECTIVENESS ANALYSIS OF STANDARD PROPHYLAXIS VERSUS ON-DEMAND TREATMENT IN SEVERE HEMOPHILIA A IN CHINA
    Fang, H.
    Chen, C.
    Han, L.
    Wu, J.
    VALUE IN HEALTH, 2017, 20 (05) : A219 - A220
  • [8] Prophylactic versus on-demand treatment with rFVIIa in hemophilia patients with inhibitors: A decision-model analysis
    Doti, C.
    HAEMOPHILIA, 2012, 18 : 176 - 176
  • [9] Cost-effectiveness Analysis of Prophylaxis Versus On-demand Treatment for Children With Hemophilia B Without Inhibitors in China
    Liu, Guoqing
    Xin, Qing
    Chen, Zhenping
    Li, Lanting
    Chen, Ting
    Wu, Runhui
    CLINICAL THERAPEUTICS, 2021, 43 (09) : 1536 - 1546
  • [10] US COST EFFECTIVENESS ANALYSIS OF PRIMARY PROPHYLAXIS VERSUS ON-DEMAND TREATMENT IN HEMOPHILIA: DESIGN AND RATIONALE OF A COMPREHENSIVE MODEL
    Boer, R.
    Lalla, A.
    Mathew, P.
    Preblick, R.
    Pocoski, J.
    VALUE IN HEALTH, 2010, 13 (03) : A216 - A216
12